Therapies in the pipeline for small-cell lung cancer.

Related Articles

Therapies in the pipeline for small-cell lung cancer.

Br Med Bull. 2016 Jun 20;

Authors: Romanidou O, Imbimbo M, Mountzios G, Abidin A, Morgillo F, Califano R

Abstract
INTRODUCTION OR BACKGROUND: Small-cell lung cancer (SCLC) represents ~15% of all cases of lung cancer and is characterized by a rapid tumour doubling time, early onset disease dissemination and high sensitivity to chemotherapy.
SOURCES OF DATA: We searched MEDLINE and OVID databases for articles in English published from January 1980 to February 2015.
AREAS OF AGREEMENT: Platinum-based chemotherapy, thoracic radiotherapy and prophylactic cranial irradiation are standard of care. Benefit from second-line chemotherapy is limited.
AREAS OF CONTROVERSY: The role of platinum/irinotecan chemotherapy in the Western population and the role of maintenance therapies remain to be established.
GROWING POINTS: Knowledge of the biology of SCLC has expanded exponentially and many potential therapeutic targets have been identified.
AREAS TIMELY FOR DEVELOPING RESEARCH: The use of circulating tumour cells can help investigating molecular alterations occurring within tumour cells, understanding drug resistance mechanisms and evaluating new treatments.

PMID: 27325208 [PubMed - as supplied by publisher]

from #MedicinebyAlexandrosSfakianakis via xlomafota13 on Inoreader http://ift.tt/28SUrh1
via IFTTT